BNGO bionanogenomics.com: Projected Sales Volume

Graphic logo of Bionano Genomics, Inc. (BNGO)

Bionano Genomics, Inc. (BNGO) is expanding its biotech footprint by supplying equipment to oncology centers and geneticists. The business is centered around the Saphyr ecosystem, where the compatibility of software and chips ensures customer retention. The company's projected sales figures confirm this potential, with the current metric standing at 0.03. Growth is further supported by autonomous robots that eliminate human error during DNA analysis.

Company Revenue Forecast: bionanogenomics.com (BNGO) for 07/04/2022 - 11/18/2026

Metric breakdowns and analytics for Bionano Genomics, Inc. (BNGO)

- stock quotes and analyst forecast:
Basic company analysis:Bionano Genomics, Inc.
Signature product of Bionano

Fundamental screening of a defensive portfolio requires separating market noise from actual revenue growth rates. This indicator mathematically assesses expected cash inflows, identifying the asymmetry between the current price and the business's recovery potential. For Bionano Genomics, Inc. (BNGO), the metric reflects the expansion efficiency of Saphyr systems and software penetration into the digital DNA segment. The trend in the company's future sales levels allows for an objective assessment of the scale of B2B market capture. Analyzing this indicator helps investors determine the fair value of the assets.

Competitors of Bionano Genomics, Inc.

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|Company Projected Revenue metagenomi.co|Projected Sales Volume Precision BioSciences Inc.|Projected Sales Volume GBIO|Boundless Bio, Inc. - Company Revenue Forecast|Projected Sales Volume XCUR (Exicure, Inc.)|Company Future Sales Imunon, Inc. (IMNN)|PHIO - Company Projected Revenue|Company Future Revenue MBIO (mustangbio.com)|RNAZ: Projected Sales Volume|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume